A Agilent Technologies Inc.

Agilent Named Company of the Year by Instrument Business Outlook

Agilent Technologies Inc. (NYSE: A) today announced that it has been selected as 2017 Company of the Year by Instrument Business Outlook (IBO).

IBO is a respected industry newsletter that tracks trends in the laboratory products markets, monitoring hundreds of life science and analytical instrument companies on a daily basis.

Managing Editor Tanya Samazan noted: "Agilent has grown sales since fiscal 2015 while keeping costs constant. The company’s fiscal 2017 revenue growth was its fastest since fiscal 2010. Agilent’s new investments have also paid off. Changes include an expansion of Agilent’s diagnostics business, entry into new markets such as cell analysis and Raman spectroscopy, and additions to successful franchises in NGS sample preparation and LC/MS, among other key product launches."

“We are pleased that IBO has recognized Agilent as their 2017 Company of the Year, citing our impressive growth,” said Mike McMullen, Agilent's president and CEO. “Having the right strategy to secure growth is pivotal, but equally crucial is the right team, resolute in their commitment, and with one focus - to provide solutions and services which enable Agilent´s customers to be successful across the all the markets we serve.”

The newsletter highlighted Agilent’s increased growth in revenues, operating profit, and net income, noting that the gains were the result of a sustained effort to position the company for future growth.

“It is rewarding that an organization with an in-depth knowledge of the industry, such as IBO, recognizes Agilent´s current strategy is the right one resulting in consistent growth,” said Patrick Kaltenbach, president of Agilent's Life Sciences and Applied Markets Group. “Growth fueled by our focus on Innovation with Purpose, introducing differentiated solutions to address customer needs, and our strong Operational Excellence in developing, manufacturing and commercialization of our products, all complemented by our recent acquisitions.”

IBO is a twice-monthly publication of SDi, a division of BioInformatics LLC, which offers custom market research and consulting, and strategic advisory services. IBO will present the award to Agilent at the annual conference of the Society for Laboratory Automation and Screening (SLAS) in San Diego in early February.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers' most challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and employs 13,500 people worldwide. Information about Agilent is available at www.agilent.com.

EN
22/01/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Agilent Technologies, Inc.: Key facts and statistics - fiscal 2025

A summary company profile, detailing Agilent Technologies, Inc.’s business operations and financial highlights.

Agilent Technologies, Inc. - October 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Agilent Technologies, Inc.: Update to credit analysis

Our credit view of this issuer reflects its low financial leverage, against its high proportion of revenue from costly equipment sales, which has exposure to cyclical demand fluctuations

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 December 2025 in which we reassessed the appropriateness of the ratings in th...

Agilent Technologies Inc: 1 director

A director at Agilent Technologies Inc sold 2,600 shares at 149.812USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch